Stopping Weight Loss Drugs Doubles Heart Attack Risk

Stopping GLP-1 medications, commonly known as fat jabs, has been linked to a doubled risk of heart attack, stroke, or death in individuals with type 2 diabetes, according to a recent study. This research, published in The Lancet Regional Health - Europe, examined data from over 80,000 patients across more than 300 diabetes clinics in Italy.

The study observed that participants who continued their GLP-1 treatment experienced approximately half the risk of major adverse cardiovascular events compared to those who ceased treatment. This association persisted even when factors like weight regain, blood sugar, and blood pressure levels were considered, suggesting a potential direct impact of stopping the drugs on cardiovascular health.

Researchers emphasized that the study was observational, meaning it could not definitively prove causation. However, the findings underscore the importance of continued treatment for patients with type 2 diabetes who benefit from GLP-1s. Experts suggest that supporting patients to remain on effective treatments is crucial for mitigating cardiovascular risks.